WO2020138761A1 - Virus chimère du virus du syndrome reproducteur et respiratoire porcin, et vaccin l'utilisant - Google Patents

Virus chimère du virus du syndrome reproducteur et respiratoire porcin, et vaccin l'utilisant Download PDF

Info

Publication number
WO2020138761A1
WO2020138761A1 PCT/KR2019/017319 KR2019017319W WO2020138761A1 WO 2020138761 A1 WO2020138761 A1 WO 2020138761A1 KR 2019017319 W KR2019017319 W KR 2019017319W WO 2020138761 A1 WO2020138761 A1 WO 2020138761A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
lmy
nucleic acid
acid sequence
polynucleotide
Prior art date
Application number
PCT/KR2019/017319
Other languages
English (en)
Korean (ko)
Inventor
조선희
박창훈
백종혁
차상호
강석진
유수화
조인수
Original Assignee
주식회사 바이오포아
대한민국(농림축산식품부 농림축산검역본부장)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190145389A external-priority patent/KR102335864B1/ko
Application filed by 주식회사 바이오포아, 대한민국(농림축산식품부 농림축산검역본부장) filed Critical 주식회사 바이오포아
Priority to CN201980093073.0A priority Critical patent/CN113544140A/zh
Publication of WO2020138761A1 publication Critical patent/WO2020138761A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Definitions

  • the present invention relates to a chimeric virus of porcine genital and respiratory syndrome virus (PRRSV) that can be used as a vaccine, and the chimeric virus of the present invention has lower pathogenicity and higher safety than the parent strain.
  • PRRSV chimeric virus of the present invention improves the secretion of neutralizing antibodies related to cross-immunity, and can provide a vaccine that can effectively protect porcine genital and respiratory syndrome.
  • PRRS Porcine Reproductive and Respiratory Syndrome
  • PRRS The viral disease was first discovered in the United States in 1987, then in Europe, and was identified in Asia in the early 1990s. So far, PRRS has been characterized by endemic disease in swine countries and has spread worldwide, causing huge economic losses every year.
  • the pathogens responsible for PRRS are the PRRS virus belonging to the genus Arterivirus, Arteriviridae, and Nidovirales.
  • the PRRS virus has a positive-sense single stranded RNA genome and is about 15.4 kilobase in size.
  • the genome of the PRRS virus has 9 ORFs (Conzelmann et al., 1993; Meulenberg et al., 1993).
  • ORF1a and ORF1b encoding non-structural proteins (NSPs) account for about 80% of viral genomes (Bautista et al., 2002; Meulenberg et al., 1993; Snijder and Meulenberg, 1998, 2001) .
  • NSP1-alpha, NSP-1 beta, NSP2 to NSP8 are located in ORF1a, and NSP9 to NSP12 are located in ORF1b among the non-structural proteins.
  • the glycosylated structural proteins GP2, GP3, GP4, GP5, non-glycosylated membrane (Membrane, M) protein, and nucleocapsid (N) protein are encoded by ORF2-7, which accounts for the remaining 20%.
  • the minor structural proteins GP2, GP3, and GP4 form heterotrimers, which act when viruses enter the host cell.
  • the major structural proteins, GP5, M form heterodimers to increase the infectivity of the virus.
  • PRRS virus is highly mutated due to the nature of the RNA virus, so there are many differences between the viruses.
  • PRRS virus is largely divided into North American and European. Type I representing the European type (Lelystad virus, LV) and Type II representing the North American strain ATCC VR2332 (for genome sequence of VR2332, refer to GenBank accession number AY150564) (Murtaugh et al., Arch Virol. 1995; 140:1451-1460).
  • the current attenuated vaccine can be produced only through successive passages of 100 to 200 or more passages in cell lines of other animal species, so there is a problem that the development period is long and the efficacy and safety are difficult to be guaranteed. Because of this, a standard mutant-based vaccine is produced for each, but it is not effectively preventing PRRS because of its poor cross-defense ability.
  • the present invention relates to a chimeric virus of porcine genital and respiratory syndrome virus (PRRSV) that has low pathogenicity, high stability, and improved secretion of neutralizing antibodies, a vaccine comprising the same, and a method for manufacturing the same.
  • PRRSV porcine genital and respiratory syndrome virus
  • the chimeric virus is
  • nucleic acid sequence of ORF1a and ORF1b derived from the LMY ver2 mutant strain of accession number KCTC 13394BP or a nucleic acid sequence having 70% or more sequence homology with the nucleic acid sequence while maintaining functional equivalence thereto, and
  • the present invention relates to a chimera virus of porcine reproductive and respiratory syndrome (PRRS) virus that can be used as a vaccine.
  • PRRS porcine reproductive and respiratory syndrome
  • the PRRSV chimeric virus of the present invention is attenuated more than the parent strain, and thus has low pathogenicity and high stability, and significantly improves the immunity of pigs by improving the secretion of neutralizing antibodies capable of cross-immunization. Therefore, it can be used as a vaccine for effective prevention and treatment of PRRS disease.
  • attenuated virus refers to a non-toxic virus that is capable of eliciting an immune response in a target mammal without causing clinical signs of PRRS disease, and is also an attenuated virus infected and attenuated virus It may also mean that the incidence of clinical signs is lowered in animals that have not been dosed with, or that the severity of the signs is reduced compared to "control" animals infected with the non-attenuated PRRS virus.
  • the term “reduced/reduced” refers to a reduction of at least 10%, preferably 25%, more preferably 50%, most preferably 100% or more compared to the control group defined above.
  • Vaccine composition as used herein may be a PRRS chimeric virus or any immunogenic fragment or fraction thereof, preferably an attenuated PRRS chimeric virus, such as the PRRS chimeric virus of the present invention. This causes the host's “immunological response” to be a cellular and/or antibody-mediated immune response to PRRSV. It is preferred that the vaccine composition is capable of conferring preventive immunity against PRRSV infection and clinical signs associated therewith.
  • immune response refers to any cell- and/or antibody-mediated immune response to a chimeric virus or vaccine administered to an animal receiving the PRRSV chimeric virus of the present invention, or a vaccine composition comprising the same.
  • an “immune response” includes, but is not limited to, one or more of the following effects: antibodies, B cells, helper T cells specifically directed against antigens or antigens included in the composition or vaccine. , Production or activation of inhibitor T cells and/or cytotoxic T cells and/or ⁇ T cells.
  • the host exhibit a therapeutic or prophylactic immunological response such that the resistance to new infection is improved and/or the clinical severity of the disease is reduced compared to a control group that has not been administered an immunogenic composition or vaccine.
  • This prevention will be evidenced by the lack of symptoms associated with the host infections described above, as well as a decrease in frequency or severity, as well.
  • pigs As used herein, “pigs”, “pigs” and “pigs” may be used interchangeably.
  • Vaccinating means administering the PRRSV chimeric virus described herein or a vaccine comprising it before exposure to PRRS disease.
  • Prevent or “prophylaxis” means that as a result of receiving the PRRSV virus of the present invention or a vaccine composition comprising the same, the clinical incidence of PRRS, the severity or frequency of symptoms decreases.
  • the decrease in severity or frequency is a result of comparing the PRRSV chimeric virus of the present invention or a vaccine composition comprising the same with an animal or group of animals that has not been administered.
  • the animal is preferably a pig.
  • nucleotide sequence of the present specification has been described based on DNA nucleotides, and when the type of polynucleotide is RNA, a sequence in which all or some thymine (T) in the nucleotide sequence is substituted with uracil (U) it means.
  • a specific nucleotide sequence and/or amino acid includes the sequence, essentially comprising the sequence, and/or comprising all of the sequence, and may be used by appropriate substitution as necessary. Can.
  • the present invention provides a chimeric virus attenuated against swine genital and respiratory syndrome (PRRSV), a viral disease affecting pigs.
  • PRRSV swine genital and respiratory syndrome
  • the present invention provides a polynucleotide comprising the structure of structural formula 1:
  • [X] is a nucleic acid sequence of the NSP1 gene (NSP1-alpha gene and NSP1-beta gene) of the LMY ver2 mutant strain having accession number KCTC 13394BP, or a sequence of 70% or more within a range in which functions equivalent to the nucleic acid sequence are maintained.
  • nucleic acid sequence having homology including, for example, a nucleic acid sequence of the NSP1 gene of the LMY ver2 variant strain or a nucleic acid sequence having 70% or more sequence homology within a range in which functions equivalent to the nucleic acid sequence are maintained
  • the nucleic acid sequence of the gene of the ORF1a and ORF1b regions of the LMY ver2 variant strain having the number 13394BP or the nucleic acid sequence of the gene of the genes of the ORF1a and ORF1b regions is 70% or more sequence homology
  • [Y] is accession number KCTC 13393BP It is a nucleic acid sequence having a sequence homology of 70% or more within a range in which the gene nucleic acid sequence of the ORF2 to ORF7 region of the BP2017-2 mutant strain having or a function equivalent to the nucleic acid sequence is maintained.
  • the "equivalent function” may mean the same or similar function in qualitative (active) and/or quantitative (level) with the desired function.
  • the amino acid sequence of the protein encoded by the gene may be the same as the amino acid sequence of the protein encoded by the wild type gene.
  • the [X] in the nucleic acid sequence of the NSP1 gene consisting of the nucleotide sequence of SEQ ID NO: 11, all kinds of points that occur within the range in which the amino acid sequence of the NSP1 protein encoded by the NSP1 gene remains the same It may include a mutation (silent mutation), for example, can be freely selected and used within a target range for lowering the CBP level of the NSP1 gene.
  • [X] in the nucleic acid sequence of the NSP1 gene consisting of the nucleotide sequence of SEQ ID NO: 11, position 222, position 225, position 237, position 240, position 252, position 306, position 309 Position, Position 312, Position 315, Position 324, Position 327, Position 330, Position 333, Position 336, Position 339, Position 342, Position 345, Position 357, Position 363, Position 366, Position 378, Position 379, Position 381, Position 393, Position 396, Position 543, Position 546, Position 549, Position 555, Position 558, Position 561, 573 Position, Position 579, Position 582, Position 588, Position 612, Position 618, Position 621, Position 627, Position 633, Position 639, Position 654, Position 673, Position 675, Position 678, Position 681, Position 684, Position 705, Position 708, Position 729, Position 735, Position 738, Position 741, Position 744, Position 747, Position 771, Position 786 Position,
  • G is substituted at position 222 by C, and C is substituted at position 225 by A, 237 Variation in which position T is substituted by C, mutation in position 240 is replaced by T, mutation in position 252 is substituted by C, mutation in position 306 is substituted by C, and mutation in position 309 T is substituted with C, G at position 312 is substituted with A, C at position 315 is substituted with A, T at position 324 is substituted with C, C at position 327 is G substitution at position 330, G at position 330, A substitution, C at position 333, T substitution, C at position 336 at G, G substitution, T at position 339 as C Substituted mutation, mutation in which A at position 342 is substituted by T, mutation in which T at position 345 is substituted by A, mutation in which A at position 357 is substituted by G, substitution at T at position 363 is
  • the [X] is the nucleic acid sequence of the NSP1 gene (SEQ ID NO: 12) and/or NSP1-beta (SEQ ID NO: 1; 5'terminal 609 base site of SEQ ID NO: 12) with the LMY ver2 variant having accession number 13394BP, Or 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99 within the range of maintaining the function equivalent to the nucleic acid sequence % Or greater than 99.5% sequence homology.
  • the [Y] is 70% or more, 75% or more, 80% or more within the range of maintaining the gene nucleic acid sequence of the ORF2 to ORF7 region of the BP2017-2 mutant strain having accession number KCTC 13393BP or equivalent function to the sequence, It may be a nucleic acid sequence having a sequence homology of 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more.
  • [A]n may be further included at the 3'end of [Y] of Structural Formula 1.
  • the n is the number of nucleotides containing the base A, may be an integer of 10 to 100.
  • 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 15 to 80, 15 to 70, 15 to 60, 15 to 50, 15 to 40, 15 to 30 , 20 to 30, may be an integer of 20 to 26.
  • the polynucleotide may be RNA, reverse transcripts of the RNA (DNA), or a combination thereof.
  • the polynucleotide may function as a genome of the PRRSV chimeric virus.
  • a chimeric virus of porcine genital respiratory syndrome virus comprising a polynucleotide having the structure of Structural Formula 1.
  • the genome of the PRRSV chimeric virus may be DNA or RNA, and preferably RNA.
  • the [X] corresponds to the NSP1 gene region, including NSP1-beta of the LMY ver2 mutant with accession number 13394BP, and may be a gene fragment obtained by treating the genome of the LMY ver2 mutant with restriction enzymes AscI and PacI. For example, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95 within a range that maintains the function equivalent to the nucleic acid sequence of SEQ ID NO: 1 and/or SEQ ID NO: 12, or the base sequence % Or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more.
  • the [Y] corresponds to the ORF2 to ORF7 region of the BP2017-2 mutant strain having accession number KCTC 13393BP, and may be a gene fragment obtained by treating the genome of the BP2017-2 mutant strain with restriction enzymes AscI and PacI, for example, a sequence 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98 within a range that maintains the nucleic acid sequence of No. 2 or equivalent function to the sequence % Or more, 99% or more, or 99.5% or more.
  • the structural formula 1 is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more within a range maintaining the function equivalent to the nucleic acid sequence of SEQ ID NO: 4 or the nucleic acid sequence , 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more.
  • it may be a nucleic acid sequence of SEQ ID NO: 4.
  • RNA polynucleotide (RNA) provided herein may include a nucleic acid sequence in which T is substituted by U among the sequences set forth in SEQ ID NOs: 1 to 4.)
  • the present invention provides a PRRSV chimeric virus comprising the polynucleotide of structural formula 1 as a genome.
  • the PRRSV chimeric virus is 1 to 80 passages, 1 to 70 passages, 1 to 60 passages, 1 to 50 passages, 1 to 40 passages, 1 to 30 passages, 1 to 20 passages, or 1 to 10 passage cultured progeny viruses It may be included.
  • [X] is the nucleic acid sequence of the NSP1 gene and/or NSP1-beta of the LMY ver2 variant with accession number 13394BP or a nucleic acid sequence having 70% or more sequence homology with the nucleic acid sequence
  • [Y] is the accession The gene nucleic acid sequence of the ORF2 to ORF7 region of the BP2017-2 variant strain having the number KCTC 13393BP or a nucleic acid sequence having 70% or more sequence homology with the nucleic acid sequence.
  • the [X] is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more of the nucleic acid sequence of the NSP1 gene and/or NSP1-beta of the LMY ver2 mutant with accession number 13394BP or the nucleic acid sequence. Or more, 95%, 96%, 97%, 98%, 99%, or 99.5% or more nucleic acid sequences.
  • the [Y] is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more with the gene nucleic acid sequence or the nucleic acid sequence of the ORF2 to ORF7 region of the BP2017-2 variant strain having accession number KCTC 13393BP , 95%, 96%, 97%, 98%, 99%, or 99.5% or more nucleic acid sequences.
  • [A]n may be further included at the 3'end of [Y] of Structural Formula 1.
  • the n is the number of nucleotides containing the base A, may be an integer of 10 to 100, for example, 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 15 to 80 , 15 to 70, 15 to 60, 15 to 50, 15 to 40, 15 to 30, 20 to 30, may be an integer of 20 to 26.
  • the polynucleotide may be RNA, reverse transcripts of the RNA (DNA), or a combination thereof.
  • the polynucleotide may function as a genome of the PRRSV chimeric virus.
  • another example of the present invention provides a chimeric virus of porcine genital respiratory syndrome virus (PRRSV) comprising a polynucleotide having the structure of Structural Formula 1.
  • PRRSV porcine genital respiratory syndrome virus
  • the genome of the PRRSV chimeric virus may be DNA or RNA, and preferably RNA.
  • the [X] corresponds to the NSP1 gene region, including NSP1-beta of the LMY ver2 mutant with accession number 13394BP, and may be a gene fragment obtained by treating the genome of the LMY ver2 mutant with restriction enzymes AscI and PacI.
  • the nucleic acid sequence of SEQ ID NO: 1 or the nucleic acid sequence and 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more It may be a nucleic acid sequence having a sequence homology of 99% or more, or 99.5% or more.
  • the [Y] corresponds to the ORF2 to ORF7 region of the BP2017-2 mutant strain having accession number KCTC 13393BP, and may be a gene fragment obtained by treating the genome of the BP2017-2 mutant strain with restriction enzymes AscI and PacI, for example, a sequence The nucleic acid sequence of No. 2 or 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more with the nucleic acid sequence, Or it may include a nucleic acid sequence having a sequence homology of 99.5% or more.
  • the structural formula 1 is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more of the nucleic acid sequence of SEQ ID NO: 4 or the nucleic acid sequence , 98% or more, 99% or more, or 99.5% or more.
  • it may be a nucleic acid sequence of SEQ ID NO: 4.
  • PRRSV chimeric virus comprising a nucleic acid sequence comprising the polynucleotide of SEQ ID NO: 4 as a genome, which was named LMY+BP2017.
  • the LMY+BP2017 virus may be a virus having accession number KCTC 13394BP.
  • the substituted variant may be a PRRSV variant strain comprising NSP1-beta.
  • the nucleotide sequence substituted in the nucleotide sequence of the gene encoding NSP1 and/or NSP1-beta of the LMY strain may be selected using a known SAVE (Synthetic Attenuated Virus Engineering) program, preferably, the present inventors It may be selected using the developed SAVE program. Specifically, the genetically safe NSP1 region in the genome of the parent strain LMY was analyzed by the SAVE program developed by the present inventors, and selected or substituted for a part or all of the nucleotide sequence showing a relatively high Codon Pair Bias (CPB). It may be a base sequence deoptimized.
  • SAVE Synthetic Attenuated Virus Engineering
  • the SAVE program can be used to quantify CPB, which is a bias caused by interaction when viral gene codons are arranged in pairs, using a computer algorithm, and the proliferation of the virus is reduced when the CPB value is deoptimized, and attenuated.
  • CPB is a bias caused by interaction when viral gene codons are arranged in pairs
  • the proliferation of the virus is reduced when the CPB value is deoptimized, and attenuated.
  • Codon Silent mutation according to the Pair Deoptimization principle can produce an attenuated LMY ver2 mutant used in the preparation of the chimeric virus of the present invention.
  • the LMY ver2 mutant may include a gene encoding the NSP1-beta protein consisting of the nucleotide sequence of SEQ ID NO: 6, or a gene encoding the NSP1 protein consisting of the nucleotide sequence of SEQ ID NO: 12.
  • the present invention can provide cells comprising the genome of the PRRSV chimeric virus of the present invention.
  • the cell refers to a cell in which the chimeric virus genome (DNA, RNA, or a vector containing the same) or the chimeric virus containing the genome is transfected in order to manufacture the chimeric virus in large quantities.
  • the type of cells is not particularly limited.
  • porcine genital respiratory syndrome virus vaccine composition comprising the PRRSV chimeric virus or a passaged cultured progeny thereof.
  • the passaged cultured progeny is a progeny virus cultured from 1 to 80 passages, 1 to 70 passages, 1 to 60 passages, 1 to 50 passages, 1 to 40 passages, 1 to 30 passages, 1 to 20 passages, or 1 to 10 passages It may be to include.
  • the vaccine may be a live vaccine or a four vaccine, but is preferably a live vaccine.
  • the attenuated PRRS chimeric virus described herein may be a modified live vaccine containing, in a surviving state, one or more virus strains described above in a pharmaceutically acceptable carrier.
  • an inactivated virus can be used to prepare a vaccine.
  • the vaccine may further include one or more selected from the group consisting of carriers, diluents, excipients, and adhuvants.
  • the pharmaceutically acceptable carrier is not particularly limited in its kind, and may include any and all solvents, dispersion media, coatings, stabilizers, preservatives, antibacterial and antifungal agents, isotonic agents, absorption delaying agents, and the like.
  • the effective amount of the attenuated chimeric virus of the present invention included in the vaccine composition may be the amount of the virus that can attract or induce an immune response in animals to which the effective dose of the virus has been administered.
  • the effective amount may depend on the vaccine components and dosing schedule.
  • the dosage of the vaccine composition is in the range of TCID 50 2 to 6, preferably 3 to 4, but may vary depending on the type of individual, but is not limited thereto.
  • the genome of the LMY-BP2017 chimeric virus of the present invention, and a vaccine composition comprising the same, can be used to prevent swine from the effects of PRRS disease.
  • subunits, including immunogenic fragments or fractions of the PRRS chimeric virus can also be used to prevent swine from the effects of PRRS disease.
  • the attenuated chimeric virus of the present invention or a vaccine composition comprising the same can be administered prophylactically before the pig is exposed to the PRRS-inducing PRRS virus strain, and can be administered to the pig at the same time the pig is exposed to the virus strain. And can be administered therapeutically after exposure of the target pig to the virus strain.
  • the vaccine composition provided by the present invention may be used for prevention of porcine genital respiratory syndrome (PRRS), for example, PRRS caused by North American PRRSV.
  • PRRS porcine genital respiratory syndrome
  • the North American PRRSV may be a type II type VR2332 virus strain.
  • the attenuated PRRSV chimeric virus of the present invention is oral, parenteral, subcutaneous, intramuscular, intradermal, sublingual, transdermal, rectal, transmucosal, surface area via inhalation, buccal administration, or its It can be administered in combination.
  • the attenuated PRRS chimeric virus can be administered in the form of an implant capable of allowing sustained release of the attenuated virus.
  • the attenuated PRRSV chimeric virus of the present invention or a vaccine composition comprising the same can be administered via injection, inhalation or transplantation, with injection being particularly preferred.
  • the attenuated PRRSV chimeric virus or vaccine composition comprising the same may be administered once or several times, and also intermittently at different dosages daily, such as for days, weeks or months.
  • the injection can be given in the desired amount or by subcutaneous or nasal spraying, or alternatively continuous injection.
  • the PRRSV chimera virus of the present invention is the TCID 50 of the virus measured by inoculating the chimeric virus and its parent strain (Accession No. GenBank accession no.DQ473474.1.) in pig lung macrophages.
  • the value of can be a virus having a TCID 50 value of 0.01 to 0.1 times compared to the TCID 50 value of the parent strain.
  • the measurement period is 2 days later, and the TCID 50 value may be 0.05 to 0.1 times.
  • the PRRSV chimeric virus of the present invention has a TCID 50 value lower than that of the parent strain, and is less attenuated and proliferative than the parent strain.
  • the PRRSV chimeric virus of the present invention and its parent strain were inoculated in pigs and the neutralizing antibody content of the mutant strain measured was 2 to 8 times, preferably Provides a virus with 2 to 4 fold. Preferably, the measurement period is 28 days later.
  • the term neutralizing antibody means an antibody having a neutralizing ability against VR2332, a representative North American PRRSV strain. Therefore, when the attenuated chimera virus of the present invention or a vaccine composition containing the same is inoculated into a pig, the titer of the neutralizing antibody of the pig increases and the immune effect on PRRS is significantly increased by increasing the expression of the pig's immune factor. I can do it.
  • the CPB value of the PRRSV chimeric virus LMY+BP2017 of the present invention described above represents a lower value than the LMY parent strain (Accession No. GenBank accession no.DQ473474.1.), preferably -0.39 To 0, more preferably -0.35 to -0.20, suitably -0.35 to -0.26, for example -0.2393184052058128.
  • the CPB level is less than -0.39, it is difficult to produce a virus, and when it exceeds 0, the operation is possible, but there is a problem in that the proliferation does not decrease and thus is not attenuated. Therefore, the attenuated LMY+BP2017 chimeric virus of the present invention preferably has the CPB level.
  • the present invention provides an LMY+BP2017 chimeric virus having a CpG, UpA value of 1.0 to 3.0 times that of a parent strain (Accession No. GenBank accession no.DQ473474.1.). Changes in the ratio of CpG and UpA inevitably occur during the deoptimization process. When the CpG and UpA levels of the eukaryotic gene are increased, cell proliferation is reduced and the virus is attenuated, thereby attenuating the virus.
  • the LMY+BP2017 chimeric virus of the present invention has higher CpG and UpA levels than the parent strain, preferably 1.0 to 3.0 times higher than the parent strain, for example, CpG of the attenuated chimeric virus of the present invention. May be 1.1753, and UpA may be 1.03.
  • the genome of the LMY ver2 mutant with accession number 13394BP is treated with restriction enzymes AscI and PacI to prepare a polynucleotide fragment, and the genome of BP2017-2 mutation having accession number KCTC 13393BP is restricted.
  • a method of producing the chimeric virus of the respiratory syndrome virus can be provided.
  • the polynucleotide fragment prepared by treating the genome of the LMY ver2 mutant with restriction enzymes AscI and PacI may include a region encoding NSP1-beta.
  • the polynucleotide fragment prepared by treating the genome of the BP2017-2 mutant with restriction enzymes AscI and PacI may include ORF2 to ORF7 sites.
  • ligase may be used, and the infectious clone prepared above may be inoculated into cells to prepare a chimeric virus.
  • the cell refers to a cell in which a chimeric virus DNA or RNA, or a vector containing it, an infectious clone, or a chimeric virus is transfected, in order to prepare a large amount of the chimeric virus, and does not specifically limit the type of cell.
  • an embodiment of the present invention may provide a composition for preventing or treating porcine genital respiratory syndrome, including the vaccine composition.
  • the composition for preventing or treating porcine reproductive and respiratory syndrome of the present invention may include additional components known to those skilled in the art, and further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions. Can.
  • Suitable formulations known in the art are preferred to use those disclosed in Remington's Pharmaceutical Science, recently Mack Publishing Company, Easton PA.
  • Carriers, excipients and diluents that may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil.
  • compositions When formulating the composition, it is usually prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and the like.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. in the composition. Is prepared. Also, lubricants such as magnesium stearate and talc are used in addition to simple excipients.
  • Liquid preparations for oral administration include suspensions, intravenous solutions, emulsions, syrups, etc.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories.
  • Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • Witepsol, Macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin may be used as a base for suppositories.
  • composition of the present invention depends on the condition and weight of the individual, the severity of the disease, the drug form, the route and duration of administration, but can be appropriately selected by those skilled in the art.
  • the composition of the present invention may be administered in an amount of 0.0001 to 1,000 mg/kg (body weight) per day.
  • the composition may be administered once a day or divided several times.
  • composition of the present invention can be administered to a subject by various routes. Any mode of administration can be expected.
  • Another example of the present invention can provide a method for preventing or treating porcine genital respiratory syndrome, comprising administering a vaccine composition of the present invention to a pig.
  • the vaccine composition comprising the chimeric virus genome of the present invention to pigs, it is possible to induce that the pig's immune response to the PRRSV antigen is enhanced, and to induce the pig's immune response to the PRRSV antigen to be enhanced, porcine genital respiratory syndrome It can provide a way to prevent or treat. Preferably it can be prevented.
  • the method includes subcutaneous injection, intravenous injection, intradermal injection, parenteral injection, intramuscular injection, needle free injection, electroporation, oral delivery, intranasal delivery, oronasal delivery, Or any combination thereof.
  • the present invention can provide a kit for performing any of the methods described above.
  • the kit reduces the clinical signs or effects of the container, preferably a vaccine composition containing the attenuated PRRS chimeric virus of the invention, a pharmaceutically acceptable carrier, adjuvant and PRRS infection, preferably PRRS frequency or severity Instructions for administering the immunogenic composition to an animal in need thereof may be included.
  • the kit can also include injection means and/or other forms of administration.
  • the kit may include a solvent.
  • the attenuated vaccine can be lyophilized and restored to a solvent to be a solution for injection and/or inhalation.
  • the solvent can be water, physiological saline, buffer or reinforcing solvent.
  • the kit can include a separation container containing the attenuated virus, solvent and/or pharmaceutically acceptable carrier.
  • the instructions for use may be labels and/or printed materials attached to one or more containers.
  • the PRRSV virus chimeric virus according to the present invention can be used to effectively defend PRRS by significantly increasing the secretion of neutralizing antibodies when inoculated into pigs, and can be usefully used as a vaccine for the treatment of PRRS.
  • 1 shows a general genomic arrangement of PRRS virus.
  • Figure 2 is a schematic diagram showing the genome sequence of the LMY + BP2017 chimeric virus synthesized by cutting and connecting a part of clones of the LMY ver2 virus and the BP2017-2 virus, respectively.
  • Figure 3 shows the phylogenetic tree of the PRRSV LMY ver2 virus and the LMY+BP2017 chimera virus.
  • FIG. 4 shows the proliferative difference between PRRSV LMY ver2 virus and LMY+BP2017 chimeric virus in Porcine Alveolar Macrophage cells (PAM cells).
  • Figure 5 is a PRRSV LMY, LMY+BP2017 chimera virus in pigs, comparing the secretion of neutralizing antibodies after PBS inoculation.
  • RNA Since RNA is easily destroyed, the cells were transfected by synthesizing RNA from the DNA after converting to DNA.
  • PRRS chimera virus is a non-structural protein (NON structural Protein 1, NSP1; SEQ ID NO: 11) of the variant strain of LMY strain and ORF2, ORF3, ORF4, ORF5, ORF6 of BP2017-2 isolated in 2017 from Namsan Farm, Namsan-ri, Gongju-si, Chungnam , And ORF7 sites.
  • An LMY ver2 mutant was prepared by substituting 91 bases of the nucleotide sequence of the gene at the NSP1 site using the PRRS strain, LMY strain (GenBank accession no.DQ473474.1.), isolated from the existing quarantine headquarters.
  • the NSP1 site gene was replaced with 25 bases at the NSP1-alpha site and 66 bases at the NSP1-beta site.
  • the recombinant strain LMY ver2 is a base sequence according to the Codon Pair Deoptimization Principle (Table 3) using a generally known Synthetic Attenuated Virus Engineering (SAVE) program or SAVE (Synthetic Attenuated Virus Engineering) program developed by the present inventors. A portion of the was prepared by silent mutation (silent mutation).
  • SAVE Synthetic Attenuated Virus Engineering
  • SAVE Synthetic Attenuated Virus Engineering
  • SAVE Synthetic Attenuated Virus Engineering
  • NSP1 regions (NSP1-alphe and NSP1-beta, SEQ ID NO: 11) with high genetic stability in the genome of the LNY parent strain and analyzed them with the SAVE program, and NSP1-alpha among base regions with relatively high CPB values LMY virus mutants were prepared by deoptimization by selecting 25 bases at the site, 66 bases at the NSP1-beta site, and 91 bases, replacing them with other bases.
  • the LMY virus mutant strain in which 91 base sequences of the NSP1 prepared by the above method were mutated was referred to as LMY ver2, and the base sequences are shown in Table 3 below.
  • the LMY ver2 has accession number 13394BP.
  • the bolded and underlined portion of the nucleic acid sequence of the LMY ver2 NSP1 gene is the base portion where the mutation occurred in the LMY NSP1 gene or LMY NSP1-beta gene.
  • CPB values were measured.
  • the NSP1 CPB value of the LMY parent strain was measured to be about 0.0139 and the NSP1-beta CBP value to about 0.016, but the CPB value of the LMY ver2 variant strain of the present invention was measured to be about -0.2393 to NSP1 and about -0.33 to NSP1-beta. From this, it was found that the proliferative potential of the LMY ver2 mutant strain of the present invention is reduced compared to the existing parent strain, and is an attenuated strain.
  • the entire gene sequence (GenBank accession no.DQ473474.1.) of the LMY strain was divided into 7 fragments and synthesized.
  • Fragment 1 of the 7 fragments was an NPS-1 site, and the site was synthesized as a DNA fragment (SEQ ID NO: 12) in which 91 bases among the gene base sequences of the NSP1 site of the LMY strain were substituted.
  • the synthesized fragment gene was cut with restriction enzymes in Table 5 in order, and then linked with ligase to prepare one infectious clone.
  • the PRRS virus contains a total of 8 ORFs, namely ORF1a, ORF1b, and ORF2 to 7.
  • the LMY+BP2017 chimera virus was deposited with the Korea Research Institute of Bioscience and Biotechnology Biological Resource Center on October 24, 2018, and received the accession number KCTC13675BP.
  • the LMY+BP2017 chimeric strain was identified by sequencing the LMY+BP2017 chimeric strain synthesized in Example 1 and the NSP1 region of the LMY strain (GenBank accession no.DQ473474.1.).
  • PCR was performed using the primer set of Table 8 and one step RT PCR kit (Intron) that can be detected from 1 to 1654nt, including the NSP1 region of the LMY virus, specifically, at 45°C for 30 minutes and at 95°C 5
  • the reaction was carried out for 2 minutes at 94°C for 30 seconds and 61°C for 30 seconds at 72°C, and the process was repeated 38 times.
  • sequencing of the amplification products by PCR results was completed to identify each strain.
  • phylogenetic tree was analyzed using bioedit program and Bootstrap was repeated 1000 times. Based on this, approximate LMY+BP2017 chimera virus and LMY phylogenetic tree were prepared and are shown in FIG. 3. From the phylogenetic tree of Fig. 3, the strain of the present virus was found.
  • Example 1 When the LMY+BP2017 chimera virus prepared in Example 1 was passaged, it was confirmed how long the modified site was maintained.
  • MARC-145 cells known as PRRS virus soluble cell line the LMY+BP2017 chimera virus of the present invention was stabilized after 30 passages, and the same method as in Example 3-1 was used to confirm gene mutation every 10 passages. Sequencing was performed.
  • Table 10 shows the number of nucleotide changes (nt change), mutation site (mutataion site), and amino acid mutation (a.a change) according to each passage number.
  • swine lung macrophages (PAM, Porcine Alveolar Macrophage) inoculated with the LMY+BP2017 chimera virus and its parent strain, LMY, and then the virus produced It was confirmed by measuring the amount of TCID 50 .
  • PAM cells were dispensed at a rate of 2 X 10 6 cells/well per 6 well plates containing 2 ml of RPMI medium (including 10% FBS, 1% penicillin, and streptomycin).
  • RPMI medium including 10% FBS, 1% penicillin, and streptomycin.
  • LMY and LMY+BP2017 chimera viruses were inoculated into different wells at a rate of 0.01 of MOI, and after 1 hour of inoculation, all the supernatant was removed, and maintenance fluid RPMI medium (including 10% FBS, 1% penicillin, streptomycin) 2 ml was dispensed. Two days after dispensing, the supernatant of each well was collected to measure TCID 50 (Tissue culture infective dose 50 ).
  • the cells used in the subsequent experiments were prepared by adding 2X10 5 cell/well of MARC-145 cells to 96 wells on the day before the measurement of TCID 50 in DMEM medium (10% (v/v) FBS, 1% (w/v) penicillin, streptomycin) 100ul. It was used by dispensing with.
  • Viruses to be inoculated were prepared as follows. The supernatant collected above was dispensed in a row in 200uL to the leftmost well of a 96-well plate, and DMEM medium (FBS, no antibiotic added) was dispensed in 180 ⁇ l to the remaining wells. Next, 20 ⁇ l was collected using a multi-pipet one after the other from the left and diluted 10-fold while dispensing into the right well. The tips were diluted one after the other and the last 12th well was maintained as a negative control. The prepared virus dilution was inoculated on a plate to which MARC-145 cells were attached.
  • DMEM medium FBS, no antibiotic added
  • CPE cytopathogenic effect
  • the LMY+BP2017 chimeric strain and the parent strain LMY strain were inoculated into porcine lung macrophages (PAM cells) and the TCID 50 values measured after 1 to 2 days are shown in Tables 11 and 4 below.
  • the value of TCID 50 measured on the 2nd day when the strain was inoculated and the virus began to be harvested was LMY+BP2017 chimera, showing a TCID 50 value 100 times lower than LMY. From this, it was found that the LMY+BP2017 chimera virus of the present invention in PAM (Porcine Alveolar Macrophage) cell, which is the main infecting cell of PRRS, has at least 10-fold reduction in proliferative properties compared to LMY, and the LMY+BP2017 chimera virus of the present invention. It was confirmed that the proliferation was reduced and attenuated more than the parent strain LMY.
  • PAM Porcine Alveolar Macrophage
  • the inspection method was conducted in accordance with a known method. All serum samples were heat inactivated at 56°C for 45 minutes before starting the test. Inactivated serum was placed in RPMI 1640 medium (10% FCS, 20mM L-glutamine, antibiotic-antimycotic mixture-100IU/ml penicillin, 100 ⁇ g/ml streptomycin, 50 ⁇ g/ml gentamycin, 0.25 mg/ml amphotericin B) and doubled in sequence. Diluted. Subsequently, 100 ⁇ l of each diluted serum was collected, mixed with 100 ⁇ l of the previously prepared VR2332 strain 200 TCID 50 /ml and incubated at 37° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un virus chimère du virus du syndrome reproducteur et respiratoire porcin (PRRS), le virus chimère peut être utilisée comme vaccin. Le virus chimère de PRRSV selon la présente invention est plus atténué que sa souche parente, et favorise ainsi la sécrétion d'anticorps de neutralisation tout en ayant une faible pathogénicité et une stabilité élevée, ledit virus chimère peut ainsi être utilisé en tant que vaccin pour la prévention et le traitement efficaces de maladies de PRRS.
PCT/KR2019/017319 2018-12-27 2019-12-09 Virus chimère du virus du syndrome reproducteur et respiratoire porcin, et vaccin l'utilisant WO2020138761A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980093073.0A CN113544140A (zh) 2018-12-27 2019-12-09 猪繁殖与呼吸综合征病毒的嵌合病毒及使用其的疫苗

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20180171306 2018-12-27
KR10-2018-0171306 2018-12-27
KR10-2019-0145389 2019-11-13
KR1020190145389A KR102335864B1 (ko) 2018-12-27 2019-11-13 돼지 생식기 및 호흡기 증후군 바이러스의 키메라 바이러스 및 이를 이용한 백신

Publications (1)

Publication Number Publication Date
WO2020138761A1 true WO2020138761A1 (fr) 2020-07-02

Family

ID=71128272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/017319 WO2020138761A1 (fr) 2018-12-27 2019-12-09 Virus chimère du virus du syndrome reproducteur et respiratoire porcin, et vaccin l'utilisant

Country Status (1)

Country Link
WO (1) WO2020138761A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113215192A (zh) * 2020-02-06 2021-08-06 广西大学 猪繁殖与呼吸综合征病毒双荧光标记基因重组毒株的构建方法
CN117050196A (zh) * 2023-10-13 2023-11-14 北京纳百生物科技有限公司 一种猪繁殖与呼吸综合征病毒（prrsv）嵌合抗原及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500544A (ja) * 1994-05-13 1997-01-21 サイアナミド・イベリカ，ソシエダ・アノニマ 組換えｐｒｒｓｖタンパク、該組換えｐｒｒｓｖタンパクを含有する診断キットおよびワクチン
US7608272B2 (en) * 2005-08-30 2009-10-27 Board Of Regents Of The University Of Nebraska Methods and compositions for vaccination of animals with PRRSV antigens with improved immunogenicity
KR20150045873A (ko) * 2013-10-19 2015-04-29 건국대학교 산학협력단 돼지 생식기 호흡기 증후군 바이러스의 키메릭 변이주
KR20160099099A (ko) * 2013-12-20 2016-08-19 베링거잉겔하임베트메디카게엠베하 Ｐｒｒｓ 바이러스 변이체, 유럽형 ｐｒｒｓ 바이러스 ｃｄｎａ 클론, 및 이들의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500544A (ja) * 1994-05-13 1997-01-21 サイアナミド・イベリカ，ソシエダ・アノニマ 組換えｐｒｒｓｖタンパク、該組換えｐｒｒｓｖタンパクを含有する診断キットおよびワクチン
US7608272B2 (en) * 2005-08-30 2009-10-27 Board Of Regents Of The University Of Nebraska Methods and compositions for vaccination of animals with PRRSV antigens with improved immunogenicity
KR20150045873A (ko) * 2013-10-19 2015-04-29 건국대학교 산학협력단 돼지 생식기 호흡기 증후군 바이러스의 키메릭 변이주
KR20160099099A (ko) * 2013-12-20 2016-08-19 베링거잉겔하임베트메디카게엠베하 Ｐｒｒｓ 바이러스 변이체, 유럽형 ｐｒｒｓ 바이러스 ｃｄｎａ 클론, 및 이들의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Genbank NCBI; 25 September 2006 (2006-09-25), XP055722333, Database accession no. DQ473474.1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113215192A (zh) * 2020-02-06 2021-08-06 广西大学 猪繁殖与呼吸综合征病毒双荧光标记基因重组毒株的构建方法
CN113215192B (zh) * 2020-02-06 2023-08-11 广西大学 猪繁殖与呼吸综合征病毒双荧光标记基因重组毒株的构建方法
CN117050196A (zh) * 2023-10-13 2023-11-14 北京纳百生物科技有限公司 一种猪繁殖与呼吸综合征病毒（prrsv）嵌合抗原及其应用
CN117050196B (zh) * 2023-10-13 2024-02-02 北京纳百生物科技有限公司 一种猪繁殖与呼吸综合征病毒嵌合抗原及其应用

Similar Documents

Publication Publication Date Title
US11911454B2 (en) Effective vaccination against porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
KR101653177B1 (ko) 고병원성 돼지 생식기 및 호흡기 증후군(ｈｐ ｐｒｒｓ)에 대한 백신
Kimman et al. Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology
AU2006253891B2 (en) N Protein Mutants of Porcine reproductive and respiratory syndrome virus
JP5793197B2 (ja) 北米型ブタ繁殖・呼吸障害症候群（ｐｒｒｓ）ウイルス及びその使用
US9187731B2 (en) PRRS virus inducing type I interferon in susceptible cells
CA2892948C (fr) Composition de virus du syndrome reproducteur et respiratoire porcin et leurs utilisations
WO2020138761A1 (fr) Virus chimère du virus du syndrome reproducteur et respiratoire porcin, et vaccin l'utilisant
EP2737059A1 (fr) Nouveau virus srrp induisant un interféron de type i dans des cellules susceptibles
KR102335864B1 (ko) 돼지 생식기 및 호흡기 증후군 바이러스의 키메라 바이러스 및 이를 이용한 백신
KR102193460B1 (ko) 돼지생식기호흡기증후군 예방용 백신 조성물 및 이의 예방 방법
WO2015056850A1 (fr) Souche mutante chimère de virus du syndrome reproducteur et respiratoire porcin
KR101933932B1 (ko) 돼지 생식기 및 호흡기 증후군 바이러스 변이주 및 이를 이용한 백신
KR101933931B1 (ko) 돼지 생식기 및 호흡기 증후군 바이러스 변이주 및 이를 이용한 백신
WO2021154055A1 (fr) Souche mutante du virus du syndrome reproducteur et respiratoire porcin européen, et vaccin l'utilisant
WO2024029707A1 (fr) Souche chimérique du virus nord-américain et européen du syndrome respiratoire et reproductif porcin et son procédé de production
WO2024205358A1 (fr) Virus chimérique du syndrome reproducteur et respiratoire porcin et composition de vaccin l'utilisant
RU2781446C1 (ru) Химерный вирус репродуктивно-респираторного синдрома свиней и вакцина с использованием указанного вируса
WO2023128051A1 (fr) Virus chimérique exprimant un peptide dérivé du virus du syndrome respiratoire et productif porcin et composition de vaccin le comprenant
KR20240019015A (ko) 북미형 및 유럽형 돼지생식기호흡기증후군 바이러스의 키메라 제조방법
KR20240019014A (ko) 북미형 및 유럽형 돼지생식기호흡기증후군 바이러스의 키메라 균주
KR20230144463A (ko) 신규한 재조합 돼지 생식기 호흡기 증후군 바이러스주 kprrsv2-d3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19902856

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 18/11/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19902856

Country of ref document: EP

Kind code of ref document: A1